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Abstract  
Introduction: Pediatric acute lymphoblastic leukemia (ALL) rarely presents with hypercalcemia and diffuse 
osteolytic lesions. Presentation of Case: We report the case of a 17 year-old male with hypercalcemia, 
thrombocytopenia, and renal failure. Skeletal x-rays showed extensive osteolytic lesions. Pamidronate was used for 
treatment of hypercalcemia when calcitonin failed to maintain calcium levels within the normal range. Parathyroid 
hormone-related peptide (PTHrP) was not elevated. Bone marrow biopsy revealed B-precursor acute lymphoblastic 
leukemia. The patient failed two induction regimens but achieved remission after lymphoma-like chemotherapy. He 
continues to be in remission 7 years after double cord-blood transplantation.  
Conclusions: The present case is used to explore the etiology and treatment of hypercalcemia associated with 
pediatric ALL, and to review the literature concerning the prognostic significance of multiple osteolytic lesions in a 
pediatric leukemia patient. 
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Introduction 
Hypercalcemia is rare at diagnosis of childhood acute 
lymphoblastic leukemia (ALL) [1-3].The mechanism of 
ALL-induced hypercalcemia and osteolytic lesions is 
unclear, but is most likely related to the production of a 
factor by the tumor cells that activates osteoclasts. 
Parathyroid hormone-related peptide (PTHrP) is the 
most commonly described “osteoclast activating factor.” 
The effect of skeletal lesions on prognosis is unclear. 
Several retrospective studies reported a better outcome 
in pediatric ALL patients with skeletal lesions, while 
other studies reported no prognostic effect or even a 
worse outcome. 
Case Report 
A seventeen year-old, previously healthy, male 
presented with complaints of nocturia, malaise, 
constipation, and vomiting. On physical exam, the 
patient had minimal tenderness to palpation of the left 
paraspinous muscles in the thoracic region and mild 
mid-epigastric tenderness but no lymphadenopathy or 
hepatosplenomegaly.  
Table 1 Laboratory Data from Hospital Day 1 and Hospital Day 11 
 Hospital Day 1 Hospital Day 11 Normal Range 
Calcium 4.1 (H) 1.3 (L) (2.1-2.6 mmol/L) 
Blood urea nitrogen 24 (H) 14 (H) (2.1-8.6 mmol/L) 
Creatinine 407 (H) 115  (35-115 μmol/L) 
Phosphorus 2.2 (H) 0.7 (L) (1-1.6 mmol/L) 
Magnesium 0.6  0.37 (L) (0.53-0.86 mmol/L) 
Albumin 47  30 (L) (33-50 g/L) 
Alkaline phosphatase 182  69 (L) (80-250 U/L) 
Lactate dehydrogenase 131  —  (99-207 U/L) 
Uric acid 577 (H) 149  (119-327 μmol/L) 
Hemoglobin 158  96 (L) (125-161 g/L) 
White blood cell count 6.4  5.6  (4.5-13 x 10^9/L) 
Platelet count 80 (L) 44 (L) (150-450 x 10^9/L) 
H= high, L= low 
Initial laboratory evaluation showed elevated calcium 
(4.1 mmol/L) and phosphorus (2.2 mmol/L) with 
normal albumin and alkaline phosphatase. Blood urea 
nitrogen (24 mmol/L) and creatinine (407 mmol/L) 
were elevated. Uric acid (577 μmol/L) was elevated 
with normal LDH (Table 1). The patient had 
thrombocytopenia (80 x10
9
/L), with a normal 
hemoglobin and normal white blood count and 
differential with no circulating blasts.  
Hypercalcemia investigations revealed a normal 
25-hydroxyvitamin D with low 1, 25-dihydroxyvitamin 
D (< 26 pmol/L) and below-normal intact parathyroid 
hormone (< 10 ng/L). Parathyroid hormone-related 
peptide (PTHrP) was not elevated (0.2 pmol/L - 
reference <2.0 pmol/L). Macrophage 
colony-stimulating factor (M-CSF) was normal (711.4 
pg/ml - range 253-1715 pg/ml from 40 normal samples 
tested). Serum and urine protein electrophoresis, 
thyroid-stimulating hormone, and liver function tests 
were within normal limits. Antibodies to HTLV 1 and 2 
were negative.  
Skeletal survey revealed extensive lytic lesions 
involving the skull, pelvis, inferior ribs, proximal 
humeri, and proximal femora (Fig. 1. A-B). A bone scan 
revealed pathologic fractures in a lower right rib and the 
T8 vertebra, but otherwise underestimated the extent of 
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bony involvement. A head, chest, and abdominal CT 
scan confirmed numerous osteolytic lesions (Fig. 
1.C-D). The osteolytic lesions of the calvarium were 
confined to the marrow space and did not involve the 
inner or outer table. Radiographic findings suggested a 
disseminated infiltrating lesion involving the marrow 
space. There was no periosteal reaction of the long 
bones or metaphyseal bands as are sometimes seen in 
ALL. The radiologic differential diagnosis focused on 
histiocytosis, leukemia, or lymphoma.  
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone marrow aspiration and biopsy revealed densely 
packed marrow. Flow cytometry confirmed B-precursor 
acute lymphoblastic leukemia with aberrant expression 
of CD13. Standard cytogenetics with multi-colored 
fluorescent in situ hybridization (FISH) showed a 
hypodiploid karyotype with complex abnormalities 
including loss of chromosome 13 [-13], deletions of 6q 
[del(6)(q15q21)] and 12p [del(12)(p13)], and abnormal 
chromosomes 11 [add(11)(p15)] and 21 [idic(21)(q22)]. 
Interphase FISH studies showed no evidence of 
rearrangements involving BCR/ABL1 or MLL while 
ETV6/RUNX1 confirmed the 12p- and idic(21q) 
rearrangements. Cerebrospinal fluid (CSF) was 
negative for malignant cells. 
The patient was initially treated with intravenous 
normal saline and oral allopurinol. Hydration therapy 
resulted in slight improvement of the hypercalcemia 
without significant improvement in renal function. 
Calcitonin, given on hospital days three through five, 
achieved only temporary improvement of calcium 
levels. Subsequently, intravenous pamidronate (0.9 
mg/kg) was given on hospital day six with resultant 
normalization of serum calcium within 24 hours. 
Rasburicase was used on day three of hospitalization, 
with a resultant decrease in serum uric acid to < 6 
μmol/L by day 4 (Fig. 2).  
The patient’s renal function improved significantly 
after resolution of hyperuricemia and continued to 
normalize as calcium declined (Table 1).  
Methylprednisone was given on hospital day 4 (as 
C D 
Skeletal Survey  
A. Lateral view of 
the skull showing 
“mottled” 
appearance.  
B. Diaphysis of right 
right humerus from 
skeletal survey 
showing 
“scalloping” 
(arrows) 
Computed 
Tomography 
C. and D. Cuts 
through the 
calvarium showing 
“moth-eaten” 
appearance 
 Peterson K et al. American Journal of Cancer Case Reports 2013, 1:73-78 
  
Ivy Union Publishing | http: //www.ivyunion.org August 22, 2013 | Volume 1 | Issue 2
  
Page 4 of 6 
treatment for the hypercalcemia) followed by induction 
with vincristine, dexamethasone, daunorubicin, and 
PEG-asparaginase. The patient did not achieve a 
remission with this regimen. A subsequent re-induction 
attempt with etoposide, cyclophosphamide, high-dose 
methotrexate and vinblastine followed by consolidation 
with cyclophosphamide, 6-MP, and cytarabine also 
failed to induce a remission. Using a B-cell lymphoma 
chemotherapy backbone (cyclophosphamide, 
vinblastine, prednisone, doxorubicin, and high-dose 
methotrexate), a remission was demonstrated on both 
bone marrow aspiration and biopsy. This was followed 
by a consolidation regimen consisting of clofarabine 
and cytarabine. He underwent unrelated double cord 
blood transplantation and rapidly achieved 100% donor 
engraftment. The patient continues in remission 7 years 
after a bone marrow transplant with no renal 
abnormalities or skeletal complaints.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Hypercalcemia is commonly seen with some adult 
hematologic malignancies such as multiple myeloma 
and adult T-cell lymphoma. However, hypercalcemia is 
not commonly associated with pediatric cancer. A large 
retrospective study that included more than 6,000 
pediatric cancer patients (2,816 of whom had acute 
leukemia or lymphoma) reported a 0.4% incidence of 
hypercalcemia. In the group of patients with acute 
leukemia or lymphoma, the incidence of hypercalcemia 
at diagnosis was < 0.3%.1 Hibi et al. reported a higher 
incidence (4.8%) of hypercalcemia in a retrospective 
study that included 83 patients with early pre B-cell 
ALL[2] .  
Tumor cells may induce hypercalcemia by directly 
invading bone or by producing factors that locally or 
systemically activate osteoclasts [3]. Some of the 
factors that have been implicated for their potential to 
induce hypercalcemia are included in Table 2.  
Receptor activator of nuclear factor kappa-B ligand 
(RANKL), a protein encoded by gene tumor necrosis 
factor (ligand) superfamily, member 11 (TNFSF11), has 
been implicated as a possible mediator of 
hypercalcemia in cancer [5]. TNFSF11 is located in 
G-band region 13q14.11 [NC_000013.10 
(43136872..43182149)] [9]. Interestingly, our patient 
and a patient reported by Shimonodan et. al.[10] have 
lost one chromosome 13. Their patient’s homologue 13 
appeared to have an interstitial deletion involving 
G-band region 13q14-q22, while our patient had a 
normal appearing homologue 13. They found no 
expression of RANKL by immunohistochemistry 
suggesting a homozygous deletion of TNFSF11 
[10].We were not able to test for the expression of 
RANKL by immunohistochemistry. We employed FISH 
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analysis to determine if our patient had a microdeletion 
involving region 13q14 using two commercially 
available probes for RB1 and FKHR [locus FOXO1]. 
The FISH study showed no evidence of a deletion of 
either the RB1 or FKHR probes. But since TNFSF11 is 
proximal to both of these loci, a deletion of TNFSF11 
may be present and not detectable by using either the 
RB1 or FKHR probe. To our knowledge RANKL 
overexpression has not been found in ALL. 
Pamidronate proved very effective in reducing serum 
calcium levels in our patient. Pamidronate appears safe 
and effective in treating hypercalcemia associated with 
ALL [11].Dosing for pamidronate has been reported in 
a range of 0.5 to 2 mg/kg. Hypocalcemia and 
hypomagnesaemia can be a complication of the use of 
pamidronate. 
Radiographic changes at leukemia diagnosis include 
osteopenia, radiolucent metaphyseal bands, periosteal 
new bone formation, and lytic and sclerotic lesions. 
Radiographic bone lesions at diagnosis have been 
reported in 41-70% of children with acute 
lymphoblastic leukemia [12]. We found 10 retrospective 
studies that evaluated the impact of bony lesions on the 
prognosis of pediatric leukemia [12-21]. Three 
retrospective studies published between 1985 and 1998 
reported improved prognosis in patients with bone 
lesions [12-14].This is in contrast to three studies 
published between 1972 and 1996 which concluded that 
bony lesions have no impact on prognosis in pediatric 
patients with ALL [15-17]. Finally three studies 
published between 1976 and 1983 concluded that 
patients with three or more bony lesions have a worse 
prognosis than those patients without bony lesions 
[18-20].In addition, a study published in 1994 reported 
a worse prognosis in patients with 5 or more bony 
lesions compared to patients with one to four lesions.21 
The discrepancies between these studies makes it 
difficult to draw conclusions about the prognostic 
impact of skeletal lesions in pediatric ALL. These 
studies included patients treated as early as 1963 and as 
late as 1995—a time period during which treatment and 
survival of pediatric patients with ALL changed 
dramatically. Skeletal lesions will remain important 
clues to help diagnose ALL. It is unclear if they will 
have a strong role in predicting prognosis. 
Table 2 Factors Associated With Hypercalcemia of Malignancy 
 
Factor Reference  
Number 
TNF-α, TNF-β [4, 5] 
IL-1α, IL-1β, IL-6 [4, 5] 
TGF-α, TGF-β [4] 
PTHrP [4, 5] 
ectopic PTH [3]  
1,25 dihydroxyvitamin D [4] 
PG-E1, PG-E2 [6]  
RANKL [5]  
MIP-1α [7]  
M-CSF [8] 
Lymphotoxin [4] 
 
TNF=tumor necrosis factor; IL=interleukin; TGF=transforming 
growth factor; PTHrP=parathyroid hormone-related peptide; 
PTH=parathyroid hormone; PG=prostaglandin; RANKL=receptor 
activator of nuclear factor κB, ligand/osteoprotegerin system; 
MIP=macrophage inflammatory protein; M-CSF=macrophage 
colony-stimulating factor 
 
The present case has similar characteristics to 
pediatric patients with ALL and hypercalcemia 
described by Soni, (age 10-20 years, severe osteolytic 
bone lesions, lymphoblastic leukemia, and normal 
white cell count with rare or absent circulating blasts) 
[22].The patient’s presentation with gastrointestinal 
symptoms is similar to other pediatric ALL patients 
with hypercalcemia and osteolytic lesions [22]. This is 
in contrast to most children with ALL who present 
commonly with fever, bleeding, malaise, and/or bone 
pain.  
Conclusion 
In conclusion, this case demonstrates the complex 
evaluation required for childhood ALL patients who 
present with hypercalcemia and osteolytic lesions. 
Further investigations are needed to clarify the 
molecular mechanism involved in ALL-associated 
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hypercalcemia  
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